Skip to main content
Fig. 6 | Cancer Cell International

Fig. 6

From: Metformin exerts anti-AR-negative prostate cancer activity via AMPK/autophagy signaling pathway

Fig. 6

Metformin resisted prostate cancer growth in vivo. a Photos of tumors collected from the mice. DU145 cells were injected into anterior armpit of BALB/c male nude mice (n = 4 for each group). Then the mice were treated with metformin or PBS by daily oral administration. b, c Tumor volume and body weight of mice were recorded every 3 days. d The serum levels of ALT, AST, BUN, and Scr in mice from each group were detected. e, f Immunohistochemical analysis of p-AMPK, LC3B, and Ki67 for the two groups. Data are presented as the mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001 compared with the control group

Back to article page